Near fatal case of mirvetuximab soravtansine-gynx induced interstitial lung disease and a review of the primary literature.

Autor:	Clark J; University of North Carolina - Chapel Hill, Division of Pulmonary and Critical Care Medicine, USA., Blake A; University of North Carolina - Chapel Hill, Division of Pulmonary and Critical Care Medicine, USA., Vasher S; University of North Carolina - Chapel Hill, Division of Pulmonary and Critical Care Medicine, USA., Boucher RC; University of North Carolina - Chapel Hill, Division of Pulmonary and Critical Care Medicine, USA., Jones AR; University of North Carolina - Chapel Hill, Division of Gynecology Oncology, USA., Choi HJ; University of North Carolina - Chapel Hill, Division of Pulmonary and Critical Care Medicine, USA., Albright BB; University of North Carolina - Chapel Hill, Division of Gynecology Oncology, USA.
Jazyk:	angličtina
Zdroj:	Gynecologic oncology reports [Gynecol Oncol Rep] 2024 Aug 22; Vol. 55, pp. 101486. Date of Electronic Publication: 2024 Aug 22 (Print Publication: 2024).
DOI:	10.1016/j.gore.2024.101486
Abstrakt:	•Mirvetuximab soravtansine-gynx should be recognized as a cause of drug-induced interstitial lung disease (ILD).•Radiographic manifestations of mirvetuximab soravtansine-gyn induced ILD include organizing pneumonia pattern.•Interstitial lung disease related to mirvetuximab soravtansine-gyn can cause high morbidity.•Corticosteroids are commonly used in drug-induced interstitial lung disease and should be considered when encountering ILD related to mirvetuximab.•Changes to manufacturer dosing guidelines for grade 1 pneumonitis related to mirvetuximab soravtansine-gyn need to be considered. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2024 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu